| Revenues, Expenses and Operating Income (Loss) by Market Segment |
The Company does not measure the performance of its segments on any
asset-based metrics. Therefore, segment information is presented
only for operating income (loss). Revenues, expenses and operating
income (loss) by market segment were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the Three Months Ended
June 30, |
|
|
For the Six Months Ended
June 30, |
|
| |
|
2015 |
|
|
2014 |
|
|
2015 |
|
|
2014 |
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cosmeceutical market
|
|
$ |
884 |
|
|
$ |
746 |
|
|
$ |
1,725 |
|
|
$ |
1,549 |
|
|
Biomedical market
|
|
|
931 |
|
|
|
842 |
|
|
|
1,712 |
|
|
|
1,688 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
1,815 |
|
|
|
1,588 |
|
|
|
3,437 |
|
|
|
3,237 |
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Therapeutic market
|
|
|
1,316 |
|
|
|
2,388 |
|
|
|
3,552 |
|
|
|
4,608 |
|
|
Cosmeceutical market
|
|
|
777 |
|
|
|
785 |
|
|
|
1,489 |
|
|
|
1,573 |
|
|
Biomedical market
|
|
|
659 |
|
|
|
658 |
|
|
|
1,299 |
|
|
|
1,364 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
2,752 |
|
|
|
3,831 |
|
|
|
6,340 |
|
|
|
7,545 |
|
|
Operating income (loss):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Therapeutic market
|
|
|
(1,316 |
) |
|
|
(2,388 |
) |
|
|
(3,552 |
) |
|
|
(4,608 |
) |
|
Cosmeceutical market
|
|
|
107 |
|
|
|
(39 |
) |
|
|
236 |
|
|
|
(24 |
) |
|
Biomedical market
|
|
|
272 |
|
|
|
184 |
|
|
|
413 |
|
|
|
324 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating loss
|
|
$ |
(937 |
) |
|
$ |
(2,243 |
) |
|
$ |
(2,903 |
) |
|
$ |
(4,308 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues, expenses and operating income (loss) by market segment
were as follows (in thousands):
|
|
|
|
|
|
|
|
|
| |
|
For the Years Ended
Ended December 31, |
|
| |
|
2014 |
|
|
2013 |
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
Cosmeceutical market
|
|
$ |
3,507 |
|
|
$ |
3,204 |
|
|
Biomedical market
|
|
|
3,510 |
|
|
|
2,943 |
|
|
|
|
|
|
|
|
|
|
|
Total revenues
|
|
|
7,017 |
|
|
|
6,147 |
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Therapeutic market
|
|
|
9,695 |
|
|
|
8,200 |
|
|
Cosmeceutical market
|
|
|
3,253 |
|
|
|
2,914 |
|
|
Biomedical market
|
|
|
2,749 |
|
|
|
2,579 |
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
15,697 |
|
|
|
13,693 |
|
|
Operating income (loss):
|
|
|
|
|
|
|
|
|
|
Therapeutic market
|
|
|
(9,695 |
) |
|
|
(8,200 |
) |
|
Cosmeceutical market
|
|
|
254 |
|
|
|
290 |
|
|
Biomedical market
|
|
|
761 |
|
|
|
364 |
|
|
|
|
|
|
|
|
|
|
|
Total operating loss
|
|
$ |
(8,680 |
) |
|
$ |
(7,546 |
) |
|
|
|
|
|
|
|
|
|
|
| Summary of Significant Revenues in Following Regions |
Significant revenues in the following regions are those that are
attributable to the individual countries within the region to which
the product was shipped (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For the Three Months Ended
June 30, |
|
|
For the Six Months Ended
June 30, |
|
| |
|
2015 |
|
|
2014 |
|
|
2015 |
|
|
2014 |
|
|
North America
|
|
$ |
1,470 |
|
|
$ |
1,318 |
|
|
$ |
2,770 |
|
|
$ |
2,667 |
|
|
Asia
|
|
|
269 |
|
|
|
162 |
|
|
|
482 |
|
|
|
340 |
|
|
Europe
|
|
|
70 |
|
|
|
101 |
|
|
|
160 |
|
|
|
210 |
|
|
All other regions
|
|
|
6 |
|
|
|
7 |
|
|
|
25 |
|
|
|
20 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
1,815 |
|
|
$ |
1,588 |
|
|
$ |
3,437 |
|
|
$ |
3,237 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Significant revenues in the following regions are those that are
attributable to the individual country within the region to which
the product was shipped (in thousands):
|
|
|
|
|
|
|
|
|
| |
|
For the Years Ended
December 31, |
|
| |
|
2014 |
|
|
2013 |
|
|
North America
|
|
$ |
5,632 |
|
|
$ |
4,779 |
|
|
Asia
|
|
|
943 |
|
|
|
905 |
|
|
Europe
|
|
|
393 |
|
|
|
355 |
|
|
All other regions
|
|
|
49 |
|
|
|
108 |
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
7,017 |
|
|
$ |
6,147 |
|
|
|
|
|
|
|
|
|
|
|